

Call for Participants in the ECCO Guideline on IBD and Malignancies 2025 – 2026

Context and aim of the project:

The last ECCO Guideline on IBD and Malignancies was published in 2022, necessitating an update. This project aims to develop an evidence-based ECCO Guideline on Malignancies, providing comprehensive recommendations on the risk of cancer associated with IBD and its treatment, as well as the management of IBD patients with a current or past history of malignancy. The guideline development will adhere to the Oxford Levels of Evidence methodology, incorporating a PICO-structured approach and a systematic, rigorous literature search.

Timeline:

Date	Task
July 3, 2025	Applications from all participants received
July 17, 2025	Selection of participants
July 18-25, 2025	Decision of application to be sent out
September 26, 2025	Kick-off Meeting - online
Early December, 2025	Search string to be completed by CGS Librarian
Dec. 2025 – Jan. 2026	Abstract Screening by $1^{\mbox{\scriptsize st}}$ and $2^{\mbox{\scriptsize nd}}$ Screeners
February 2026	Full-text Screening by 1 st Screener
March 2026	Collection of Literature Search Tables and first draft of statements and supporting texts
April 2026	1 st online voting round
May 2026	Revision of statements and supporting text based on results of 1^{st} online voting round
June 2026	2 nd online voting round
July 2026	Revision of statements and supporting text based on results of 2 nd online voting round
October 17 or 18, 2026	Final Consensus Meeting – in person
Sept. 14 - Nov. 2, 2026	Manuscript finalisation
November 2026	Cross check by medical writer. Manuscript revision.
December 2026	Submission to JCC

Governing Board

President Fernando Magro Portugal

President-Elect Alessandro Armuzzi Italy

Past-President Britta Siegmund Germany

Secretary Edouard Louis Belgium

Treasurer Shaji Sebastian United Kingdom

Education Officer Gionata Fiorino Italy

Scientific Officer Marietta lacucci Ireland

ECCO Office Ungargasse 6/13 1030 Vienna, Austria

 Tel.
 +43-(0)1-710 22 42-0

 E-Mail
 ecco@ecco-ibd.eu

 Url
 www.ecco-ibd.eu

SWIFT GIBAATWWXXX IBAN AT5720111 28748039100

ATU 63674955 Austrian Register of Associations N° 468755685 DPR Number: N°4003204



Working groups (WGs):

- WG1: Malignancy related to underlying IBD
- WG2: Malignancy related to IBD therapy small molecules
- WG3: Malignancy related to IBD therapy biologics
- WG4: Management of IBD in patients with recent or active malignancy

After the final post-consensus revision, the statements are no longer amenable to change and the text detailing the supportive evidence is finalised for publication in the Journal of Crohn's and Colitis (JCC).

To facilitate the process, the ECCO participants will be selected for the Workgroups of this Guideline based on applications to this call.

Committed candidates with expertise are highly encouraged to apply.

If you are:

- An ECCO Member (in good standing 2025/2026 membership) and are interested in joining one of the working groups for this project;
- Able to fully commit to the process **including participation in the two mandatory meetings:**
 - Kick-off Meeting (September 26, 2025) online
 - Final Consensus Meeting (October 17 or 18, 2026) in person, attached to UEGW

To apply online*, please <u>click here</u> and use your **ECCO Portal Credentials**.

Deadline for submission is July 3, 2025

For any questions, please contact **<u>f.ifram@ecco-ibd.eu</u>**

ECCO is looking forward to your application!

Governing Board

President Fernando Magro Portugal

President-Elect Alessandro Armuzzi Italy

Past-President Britta Siegmund Germany

Secretary Edouard Louis Belgium

Treasurer Shaji Sebastian United Kingdom

Education Officer Gionata Fiorino Italv

Scientific Officer Marietta lacucci Ireland

ECCO Office Ungargasse 6/13 1030 Vienna, Austria

 Tel.
 +43-(0)1-710 22 42-0

 E-Mail
 ecco@ecco-ibd.eu

 Url
 www.ecco-ibd.eu

SWIFT GIBAATWWXXX IBAN AT5720111 28748039100

ATU 63674955 Austrian Register of Associations N° 468755685 DPR Number: N°4003204